Theravance Biopharma, Inc. Quarterly Retained Earnings (Accumulated Deficit) in USD from Q4 2013 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Theravance Biopharma, Inc. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from Q4 2013 to Q3 2024.
  • Theravance Biopharma, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending September 30, 2024 was -$950M, a 5.49% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 -$950M -$49.4M -5.49% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$937M -$45.7M -5.12% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$921M -$44.8M -5.11% Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$909M -$55.2M -6.46% Dec 31, 2023 10-Q 2024-11-14
Q3 2023 -$901M -$57M -6.76% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$892M +$869M +49.3% Jun 30, 2023 10-Q 2023-08-09
Q1 2023 -$876M +$876M +50% Mar 31, 2023 10-Q 2023-05-10
Q4 2022 -$854M +$872M +50.5% Dec 31, 2022 10-K 2024-03-01
Q3 2022 -$844M +$850M +50.2% Sep 30, 2022 10-Q 2022-11-09
Q2 2022 -$1.76B -$101M -6.12% Jun 30, 2022 10-Q 2022-08-08
Q1 2022 -$1.75B -$146M -9.07% Mar 31, 2022 10-Q 2022-05-06
Q4 2021 -$1.73B -$199M -13.1% Dec 31, 2021 10-K 2023-03-01
Q3 2021 -$1.69B -$226M -15.4% Sep 30, 2021 10-Q 2021-11-08
Q2 2021 -$1.66B -$264M -18.9% Jun 30, 2021 10-Q 2021-08-05
Q1 2021 -$1.61B -$275M -20.6% Mar 31, 2021 10-Q 2021-05-06
Q4 2020 -$1.53B -$278M -22.3% Dec 31, 2020 10-K 2022-02-28
Q3 2020 -$1.47B -$285M -24.1% Sep 30, 2020 10-Q 2020-11-09
Q2 2020 -$1.39B -$270M -24% Jun 30, 2020 10-Q 2020-08-10
Q1 2020 -$1.33B -$247M -22.8% Mar 31, 2020 10-Q 2020-05-08
Q4 2019 -$1.25B -$236M -23.4% Dec 31, 2019 10-K 2021-02-26
Q3 2019 -$1.18B -$221M -23% Sep 30, 2019 10-Q 2019-11-08
Q2 2019 -$1.12B -$222M -24.6% Jun 30, 2019 10-Q 2019-08-05
Q1 2019 -$1.08B -$223M -25.9% Mar 31, 2019 10-Q 2019-05-10
Q4 2018 -$1.01B -$214M -26.9% Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$962M -$251M -35.3% Sep 30, 2018 10-Q 2018-11-08
Q2 2018 -$903M -$259M -40.2% Jun 30, 2018 10-Q 2018-08-02
Q1 2018 -$862M -$284M -49.2% Mar 31, 2018 10-Q 2018-05-09
Q4 2017 -$798M -$286M -55.7% Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$711M -$266M -59.8% Sep 30, 2017 10-Q 2017-11-08
Q2 2017 -$644M -$233M -56.7% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 -$578M -$214M -58.8% Mar 31, 2017 10-Q 2017-05-10
Q4 2016 -$512M -$191M -59.3% Dec 31, 2016 10-K 2018-02-28
Q3 2016 -$445M -$168M -60.8% Sep 30, 2016 10-Q 2016-11-09
Q2 2016 -$411M -$182M -79.1% Jun 30, 2016 10-Q 2016-08-09
Q1 2016 -$364M -$182M -100% Mar 31, 2016 10-Q 2016-05-10
Q4 2015 -$322M -$182M -131% Dec 31, 2015 10-K 2017-03-01
Q3 2015 -$277M -$202M -269% Sep 30, 2015 10-Q 2015-11-12
Q2 2015 -$229M -$209M -1017% Jun 30, 2015 10-Q 2015-08-13
Q1 2015 -$182M Mar 31, 2015 10-Q 2015-05-13
Q4 2014 -$139M -$139M Dec 31, 2014 10-K 2016-03-11
Q3 2014 -$75M Sep 30, 2014 10-Q 2014-11-12
Q2 2014 -$20.5M Jun 30, 2014 10-Q 2014-08-14
Q4 2013 $0 Dec 31, 2013 10-K 2015-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.